Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

• Revenue in USD (TTM)0.00
• Net income in USD-117.88m
• Incorporated2016
• Employees143.00

• Location
  Adicet Bio Inc131 Dartmouth Street, 3Rd FloorBOSTON 02116United StatesUSA
• Phone+1 (617) 482-2333
• Fax+1 (302) 655-5049
• Websitehttps://www.adicetbio.com/